Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021
[150 Pages Report] The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.
The respiratory drug delivery market by formulation segment is further divided into device type and formulation type. The types of respiratory drug delivery is categorized into metered dose inhalers, dry powder inhalers, and nebulizers. The dry powder inhalers segment is expected to witness the highest growth during the forecast period due to the advantages associated with the use of these inhalers, such as short administration & preparation time, ease of use, and fewer irritant effects.
The respiratory drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.
Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment accounts for the major share in the market during the forecast period due to increasing prevalence of asthma across the globe.
Currently, North America dominates the pulmonary drug delivery devices market, and Asia represents the second-largest regional market. Moreover, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region.
Prominent players in the respiratory drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).
Target Audience:
- Pulmonary drug delivery devices and formulation manufacturers
- Public and private physicians
- Healthcare institutions (Medical data centers)
- Research & clinical laboratories
- Distributors and suppliers of pulmonary drug delivery devices
- Health insurance companies
- Market research and consulting firms
To know about the assumptions considered for the study, download the pdf brochure
Want to explore hidden markets that can drive new revenue in Pulmonary/ Respiratory Drug Delivery Market?
This report categorizes the respiratory drug delivery market into the following segments and sub segments
Respiratory Drug Delivery Market, by Formulations
-
Type
- Suspension Aerosol
- Solution Aerosol
- Dry Powder Formulation
-
Device Type
- Metered Dose Inhalers (MDI)
- Dry Powder Inhalers (DPI)
- Nebulizers
Respiratory Drug Delivery Market, by Canister Type
- Plain Canister
- Coated Canister
Respiratory Drug Delivery Market, by Applications
- Asthma
- COPD
- Cystic Fibrosis
Respiratory Drug Delivery Market, by End User
- Hospitals &Clinics
- Homecare settings
Respiratory Drug Delivery Market, by Region
-
North America
- U.S.
- Canada
-
Europe
- Germany
- France
- U.K.
- Rest of Europe (RoE)
-
Asia
- China
- India
- Japan
- Rest of Asia (RoA)
- Rest of the World (RoW)
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to 5).
Further Split of the RoW Respiratory Drug Delivery Market
market size and growth rate estimates of Latin America, Pacific, and the Middle East & Africa.
The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. The market is witnessing growth due to factors such as increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers, and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis.
The respiratory drug delivery market is segmented based on formulations, canister type, applications, end users, and regions. The formulation segment is further divided into device type and formulation type.
The respiratory drug delivery market, by device type, is categorized into metered dose inhalers, dry powder inhalers, and nebulizers. The metered dose inhalers segment is expected to account for the largest share of the market by type of delivery by device, in 2016. Factors such as the efficient absorption of drugs through the lungs and negligible side effects (as drugs are exposed only to the lungs) are contributing to the growth of this segment.
The respiratory drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.
Based on canister type, the respiratory drug delivery market is segmented into plain canisters and coated canisters. The plain canisters segment is expected to command the largest share of the pulmonary drug delivery devices market in 2016. The market for these canisters is majorly driven by the rising incidence of COPD and increasing use of inhalers
Based on end user, the respiratory drug delivery market is segmented into hospitals & clinics and home care settings. In 2016, the home care settings segment is expected to grow at a highest CAGR of the market due to technological advancements such as digital inhalers in pulmonary drug delivery devices that enable their usage in the home care settings.
Presently, North America dominates the respiratory drug delivery market, and Europe represents the second-largest regional market. This is attributed to increasing technological developments in the form of digital inhalers developed by various companies and supportive reimbursement policies in the form of Medicare and Medicaid.
Prominent players in the respiratory drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Key Data From Primary Sources
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 23)
4 Premium Insights (Page No. - 27)
4.1 Pulmonary Drug Delivery: Market Overview
4.2 Geographic Analysis: Pulmonary Drug Delivery Market, By Application (2016)
4.3 Respiratory Drug Delivery Market, By Device Type (2016 vs 2021)
4.4 Pulmonary Nebulizers Market, By Type (2016–2021)
4.5 Geographic Snapshot: Market
5 Market Overview (Page No. - 31)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery
5.2.1.2 Increasing Focus on the Development of Smart/Digital Inhalers
5.2.1.3 Increasing Incidence of Respiratory Diseases
5.2.2 Market Restraints
5.2.2.1 Regulatory Issues
5.2.2.2 Pricing Pressure
5.2.3 Market Opportunities
5.2.3.1 Emerging Markets
5.2.3.2 Growth in Online Marketing Channels
5.2.4 Market Challenges
5.2.4.1 Issues With the Stability of Drugs
5.2.4.2 Deposition of Aerosolized Particles
6 Respiratory Drug Delivery Market, By Formulation (Page No. - 37)
6.1 Introduction
6.2 Type
6.2.1 Suspension Aerosols
6.2.2 Solution Aerosols
6.2.3 Dry Powder Formulations
6.3 Device Type
6.3.1 Metered Dose Inhalers (MDIS)
6.3.2 Dry Powder Inhalers (DPIS)
6.3.3 Nebulizers
6.3.3.1 Jet Nebulizers
6.3.3.2 Ultrasonic Nebulizers
6.3.3.3 Soft Mist Nebulizers
7 Respiratory Drug Delivery Market, By Canister Type (Page No. - 49)
7.1 Introduction
7.2 Plain Canisters
7.3 Coated Canister
8 Respiratory Drug Delivery Market, By Application (Page No. - 52)
8.1 Introduction
8.2 Chronic Obstructive Pulmonary Disease
8.3 Asthma
8.4 Cystic Fibrosis
8.5 Other Applications
9 Respiratory Drug Delivery Market, By End User (Page No. - 58)
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Home Care Settings
10 Respiratory Drug Delivery Market, By Region (Page No. - 62)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 Rest of Asia
10.5 Rest of the World
11 Competitive Landscape (Page No. - 112)
11.1 Overview
11.2 Market Rank Analysis
11.3 Competitive Situations and Trends
11.3.1 Collaborations
11.3.2 Product Launches and Regulatory Approvals
11.3.3 Acquisitions
11.3.4 Expansions
12 Company Profiles (Page No. - 118)
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 Introduction
12.2 Teva Pharmaceutical Industries Ltd.
12.3 3M
12.4 Glaxosmithkline PLC
12.5 Astrazeneca PLC
12.6 Boehringer Ingelheim
12.7 Merck & Co., Inc.
12.8 Novartis AG
12.9 Omron Corporation
12.10 Sunovion Pharmaceuticals Inc. (A Part of Sumitomo Dainippon Pharma Co., Ltd.)
12.11 Cipla Inc.
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 140)
13.1 Insights From Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (104 Tables)
Table 1 Companies Developing Smart/Digital Inhaler Technologies
Table 2 Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 3 Suspension Aerosols Market Size, By Region, 2014–2021 (USD Million)
Table 4 Solution Aerosols Market Size, By Region, 2014–2021 (USD Million)
Table 5 Dry Powder Formulations Market Size, By Region, 2014–2021 (USD Million)
Table 6 Pulmonary Drug Delivery Formulations Market Size, By Device Type , 2014–2021 (USD Million)
Table 7 Metered Dose Inhalers Market Size, By Region, 2014–2021 (USD Million)
Table 8 Dry Dose Inhalers Market Size, By Region, 2014–2021 (USD Million)
Table 9 Nebulizers Market Size, By Type, 2014–2021 (USD Million)
Table 10 Nebulizers Market Size, By Region, 2014–2021 (USD Million)
Table 11 Jet Nebulizers Market Size, By Region, 2014–2021 (USD Million)
Table 12 Ultrasonic Nebulizers Market Size, By Region, 2014–2021 (USD Million)
Table 13 Soft Mist Nebulizers Market Size, By Region, 2014–2021 (USD Million)
Table 14 Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 15 Plain Canisters Market Size, By Region, 2014–2021 (USD Million)
Table 16 Coated Canisters Market Size, By Region, 2014–2021 (USD Million)
Table 17 Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 18 Pulmonary Drug Delivery Market Size for Copd, By Region, 2014–2021 (USD Million)
Table 19 Market Size for Asthma, By Region, 2014–2021 (USD Million)
Table 20 Market Size for Cystic Fibrosis, By Region, 2014–2021 (USD Million)
Table 21 Pulmonary Drug Delivery Market Size for Other Applications, By Region, 2014–2021 (USD Million)
Table 22 Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 23 Pulmonary Drug Delivery Market Size for Hospitals & Clinics, By Region, 2014–2021 (USD Million)
Table 24 Pulmonary Drug Delivery Market Size for Home Care Settings, By Region, 2014–2021 (USD Million)
Table 25 Global Respiratory Drug Delivery Market Size, By Region, 2014–2021 (USD Million)
Table 26 North America: Pulmonary Drug Delivery Market Size, By Country, 2014–2021 (USD Million)
Table 27 North America: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 28 North America: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 29 North America: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 30 North America: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 31 North America: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 32 U.S.: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 33 U.S.: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 34 U.S.: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 35 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 36 U.S.: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 37 Canada: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 38 Canada: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 39 Canada: Respiratory Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 40 Canada: Respiratory Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 41 Canada: Respiratory Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 42 Europe: Pulmonary Drug Delivery Market Size, By Country, 2014–2021 (USD Million)
Table 43 Europe: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 44 Europe: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 45 Europe: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 46 Europe: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 47 Europe: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 48 Germany: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 49 Germany: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 50 Germany: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 51 Germany: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 52 Germany: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 53 U.K.: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 54 U.K.: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 55 U.K.: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 56 U.K.: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 57 U.K.: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 58 France: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 59 France: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 60 France: Respiratory Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 61 France: Respiratory Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 62 France: Respiratory Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 63 RoE: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 64 RoE: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 65 RoE: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 66 RoE: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 67 RoE: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 68 Asia: Pulmonary Drug Delivery Market Size, By Country, 2014–2021 (USD Million)
Table 69 Asia: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 70 Asia: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 71 Asia: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 72 Asia: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 73 Asia: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 74 China: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 75 China: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 76 China: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 77 China: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 78 China: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 79 India: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 80 India: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 81 India: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 82 India: Market Size, By End User, 2014–2021 (USD Million)
Table 83 India: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 84 Japan: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 85 Japan: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 86 Japan: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 87 Japan: Pulmonary Drug Delivery Market Size, By End User, 2014–2021 (USD Million)
Table 88 Japan: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 89 RoA: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 90 RoA: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 91 RoA: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 92 RoA: Market Size, By End User, 2014–2021 (USD Million)
Table 93 RoA: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 94 RoW: Pulmonary Drug Delivery Formulations Market Size, By Type, 2014–2021 (USD Million)
Table 95 RoW: Pulmonary Drug Delivery Formulations Market Size, By Device Type, 2014–2021 (USD Million)
Table 96 RoW: Pulmonary Drug Delivery Market Size, By Canister Type, 2014–2021 (USD Million)
Table 97 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 98 RoW: Pulmonary Drug Delivery Market Size, By Application, 2014–2021 (USD Million)
Table 99 Market Ranking of the Key Players in the Respiratory Drug Delivery Market (2015)
Table 100 Collaborations, 2014–2016
Table 101 Product Launches and Regulatory Approvals, 2014–2016
Table 102 Acquisitions, 2014–2016
Table 103 Expansions, 2014–2016
Table 104 Exchange Rate (Utilized for the Conversion of Gbp to USD)
List of Figures (33 Figures)
Figure 1 Research Design
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Global Pulmonary Drug Delivery Market Size, By Device Type, 2016 vs 2021
Figure 7 Global Market Size, By Application, 2016 vs 2021
Figure 8 Global Pulmonary Drug Delivery Market Size, By Canister Type, 2016 vs 2021
Figure 9 Global Respiratory Drug Delivery Market Size, By End User, 2016 vs 2021
Figure 10 Geographical Snapshot of the Market
Figure 11 Increasing Incidence of Respiratory Diseases is A Key Market Driver for Pulmonary Drug Delivery
Figure 12 Asthma Forms the Largest Application Segment in the Pulmonary Drug Delivery Market
Figure 13 Metered-Dose Inhalers to Command the Largest Market Share in 2016
Figure 14 Jet Nebulizers to Dominate the Pulmonary Nebulizers Market in 2016
Figure 15 China to Register Highest Growth Rate During the Forecast Period
Figure 16 Respiratory Drug Delivery Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 U.K.: Estimated Number of People Diagnosed With Asthma (2004–2012)
Figure 18 North America: Pulmonary Drug Delivery Market Snapshot
Figure 19 Europe: Market Snapshot
Figure 20 Asia: Respiratory Drug Delivery Market Snapshot
Figure 21 Key Developments in the Pulmonary Drug Delivery Market, 2014–2016
Figure 22 Battle for Market Share: Collaborations Accounted for the Largest Share of the Total Developments During 2014 to 2016
Figure 23 Geographic Revenue Mix for the Top 5 Players in the Market
Figure 24 Teva Pharmaceutical Industries Ltd.: Company Snapshot (2015)
Figure 25 3M: Company Snapshot (2015)
Figure 26 Glaxosmithkline PLC: Company Snapshot (2015)
Figure 27 Astrazeneca PLC: Company Snapshot (2015)
Figure 28 Boehringer Ingelheim: Company Snapshot (2015)
Figure 29 Merck & Co., Inc.: Company Snapshot (2015)
Figure 30 Novartis AG: Company Snapshot (2015)
Figure 31 Omron Corporation: Company Snapshot (2015)
Figure 32 Sumitomo Dainippon Pharma Co., Ltd.: Company Snapshot (2015)
Figure 33 Cipla Inc.: Company Snapshot (2016)
Generating Response ...
Growth opportunities and latent adjacency in Pulmonary/ Respiratory Drug Delivery Market